De Placido S - Search Results

1

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.

Foschini F, Napolitano F, Servetto A, Marciano R, Mozzillo E, Carratù AC, Santaniello A, De Placido P, Cascetta P, Butturini G, Frigerio I, Regi P, Silvestris N, Delcuratolo S, Vasile E, Vivaldi C, Bianco C, De Placido S, Formisano L, Bianco R. Foschini F, et al. Among authors: de placido s, de placido p. Ther Adv Med Oncol. 2020 Sep 29;12:1758835920947970. doi: 10.1177/1758835920947970. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33062062 Free PMC article.

2

External beam radiotherapy in bone metastatic prostate cancer: impact on patients' pain relief and quality of life.

Di Lorenzo G, Autorino R, Ciardiello F, Raben D, Bianco C, Troiani T, Pizza C, De Laurentiis M, Pensabene M, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Among authors: de placido s, de laurentiis m. Oncol Rep. 2003 Mar-Apr;10(2):399-404. Oncol Rep. 2003. PMID: 12579279 Review.

3

Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.

Di Lorenzo G, Autorino R, De Laurentiis M, Bianco R, Lauria R, Giordano A, De Sio M, D'Armiento M, Bianco AR, De Placido S. Di Lorenzo G, et al. Among authors: de placido s, de sio m, de laurentiis m. Tumori. 2003 Jul-Aug;89(4):349-60. doi: 10.1177/030089160308900402. Tumori. 2003. PMID: 14606635 Review.

4

Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.

De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. De Stefano A, et al. Among authors: de placido s. Cancer Chemother Pharmacol. 2011 Nov;68(5):1207-13. doi: 10.1007/s00280-011-1604-1. Epub 2011 Mar 16. Cancer Chemother Pharmacol. 2011. PMID: 21409384

5

Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials.

Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, DE Placido S, Tortora G. Carlomagno C, et al. Among authors: de placido s. Exp Ther Med. 2011 May;2(3):449-455. doi: 10.3892/etm.2011.218. Epub 2011 Feb 25. Exp Ther Med. 2011. PMID: 22977524 Free PMC article.

6

Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors.

Carlomagno C, Matano E, Bianco R, Cimminiello C, Prudente A, Pagliarulo C, Crispo A, Cannella L, DE Stefano A, D'Armiento FP, DE Placido S. Carlomagno C, et al. Among authors: de stefano a, de placido s. Exp Ther Med. 2010 Jul;1(4):611-617. doi: 10.3892/etm_00000096. Epub 2010 Jul 1. Exp Ther Med. 2010. PMID: 22993584 Free PMC article.

7

Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R. Rosa R, et al. Among authors: de stefano a, de placido s. Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19. Clin Cancer Res. 2013. PMID: 23166225

8

Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

Rosa R, Damiano V, Formisano L, Nappi L, Marciano R, Veneziani BM, De Placido S, Bianco R. Rosa R, et al. Among authors: de placido s. Oncoimmunology. 2013 Aug 1;2(8):e25123. doi: 10.4161/onci.25123. Epub 2013 May 28. Oncoimmunology. 2013. PMID: 24083076 Free PMC article.

9

Mechanisms of lapatinib resistance in HER2-driven breast cancer.

D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, Bianco R. D'Amato V, et al. Among authors: de placido s. Cancer Treat Rev. 2015 Dec;41(10):877-83. doi: 10.1016/j.ctrv.2015.08.001. Epub 2015 Aug 8. Cancer Treat Rev. 2015. PMID: 26276735 Review.

10

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.

Formisano L, D'Amato V, Servetto A, Brillante S, Raimondo L, Di Mauro C, Marciano R, Orsini RC, Cosconati S, Randazzo A, Parsons SJ, Montuori N, Veneziani BM, De Placido S, Rosa R, Bianco R. Formisano L, et al. Among authors: de placido s. Oncotarget. 2015 Sep 22;6(28):26090-103. doi: 10.18632/oncotarget.4636. Oncotarget. 2015. PMID: 26325669 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page